Transient lesion in the splenium of the corpus callosum after oral corticoid therapy.
D
D
Renard
A
A
Bonafe
C
C
Heroum
D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D001127:Arginine Vasopressin / Q000187:drug effects / Q000378:metabolism; D003221:Confusion / Q000139:chemically induced / Q000503:physiopathology; D003337:Corpus Callosum / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007405:Intervertebral Disc Displacement / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009413:Nerve Fibers, Myelinated / Q000187:drug effects* / Q000473:pathology; D010300:Parkinson Disease; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects*; D020127:Recovery of Function / Q000502:physiology; D012964:Sodium / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000502:physiology
D000893:Anti-Inflammatory Agents; D001127:Arginine Vasopressin; D012964:Sodium; D011241:Prednisone